Insilico Medicine and SK Biopharmaceuticals Sign $2.5 Billion AI Drug Discovery Deal

June 23, 2026
Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration worth up to $2.5 billion to develop drug candidates for neuroimmune disorders using Insilico’s AI platform.

Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration to discover drug candidates for neuroimmune disorders, announced in a press release. The agreement, revealed at the BIO 2026 International Convention, has a potential total value exceeding 2.5 billion dollars.

Under the partnership, Insilico will use its Pharma.AI platform for target validation, generative chemistry, and molecule optimization. SK Biopharmaceuticals will oversee late-stage development and commercialization of resulting therapies targeting neuroimmune conditions affecting the central nervous system.

Insilico will receive up to 18 million dollars in upfront and near-term milestone payments, with additional payments tied to development, regulatory, and commercial milestones. The company will also earn single-digit royalties on net sales once products reach the market.

The collaboration aims to accelerate the discovery of therapies for neuroinflammatory, neurodegenerative, and rare neurological disorders by combining Insilico’s AI-based research capabilities with SK Biopharmaceuticals’ clinical expertise.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

06/23
H3 Zoom Closes $3.6 Million Series A to Expand AI Inspection Across Asia
06/23
ChemT Biotechnology Raises $4 Million Seed Round for AI in Biomanufacturing
06/23
ECARX to Acquire Full Flyme Software Business for USD 266 Million
06/23
Tredence Acquires KMK Consulting to Expand Healthcare and Life Sciences Business
06/23
DropGenie Raises Seed+ Round to Launch Miniaturized Gene Editing Platform

More from: Life Sciences

06/23
ChemT Biotechnology Raises $4 Million Seed Round for AI in Biomanufacturing
06/23
Tredence Acquires KMK Consulting to Expand Healthcare and Life Sciences Business
06/23
Brenig Therapeutics to Present AI Designed NLRP3 Inhibitor at Keystone Symposia
06/23
DropGenie Raises Seed+ Round to Launch Miniaturized Gene Editing Platform
06/23
ChartSpan Acquires Validic to Expand Remote Patient Monitoring Platform

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like